By Kathryn Calkins
Staff writer

ImmunoGen Inc. was rewarded last week for returning to its roots, signing an agreement with SmithKline Beecham plc for its lead compound, huC242-DM1 to treat colorectal cancer. The deal marks a return by the company from an unsuccessful foray outside of its original focus, back to its root concept of creating a therapeutic window for highly toxic low molecular weight drugs by targeting them directly to cancer cells.